Checkmate Pharmaceuticals Other Current Liabilities

Checkmate Pharmaceuticals (CMPI) currently reports a other current liabilities of $8.3M as of March 2022. That compares with $5.2M in the prior-year period — up 59.5% year over year. Use the charts on this page to explore Checkmate Pharmaceuticals's other current liabilities history and peer comparisons.

Checkmate Pharmaceuticals's other current liabilities increased from $5.2M to $8.3M — a 59.5% year-over-year increase (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Checkmate Pharmaceuticals reported $8.3M in other current liabilities as of March 2022. That compares with $5.2M in the prior-year period — up 59.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $8.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Checkmate Pharmaceuticals, and consider following CMPI for alerts when major investors trade the stock.

Checkmate Pharmaceuticals is classified in the Healthcare sector. On other current liabilities, it currently shows $8.3M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CMPI with unrelated industries.